---
document_datetime: 2025-07-16 16:29:50
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 1.8032282
conversion_datetime: 2025-12-26 12:48:59.690239
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ELREXFIO

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                       |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------|
| II/0005              | Update of section 4.2 of the SmPC to add every four- week dosing schedule after at least 24 weeks of every two-week dosing and to update the recommendations for restarting therapy following dose delay, and update of sections 4.8, 5.1 and 5.2 of the SmPC with long-term efficacy, safety, and | 27/03/2025                          | 02/05/2025                                  | SmPC, Annex II and PL            | For more information, please refer to the Summary of Product Characteristics. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   | clinical pharmacology results (â‰¥2 years of follow-up after the last participant initial dose), based on the final study report of Study C1071003; a Phase 2, open-label, multicentre, non-randomised study of elranatamab monotherapy in participants with MM who are refractory to at least one PI, one IMiD, and one anti-CD38 Ab. The Package Leaflet has been updated in accordance. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and to update the list of local representatives in the Package Leaflet. Further, the provision of the final study report addresses SOB 001, and Annex II has been updated accordingly. A revised RMP version 1.3 was provided as part of the application. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/225/2 02408 | Periodic Safety Update EU Single assessment - elranatamab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 13/03/2025 | n/a        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| R/0003            | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 19/09/2024 | 13/11/2024 | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for ELREXFIO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |

<div style=\"page-break-after: always\"></div>

| PSUSA/225/2 02402   | Periodic Safety Update EU Single assessment - elranatamab                                                                                                                                                    | 19/09/2024   | 13/11/2024   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/225/202402.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0004             | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 12/09/2024   | n/a          |               |                                                                                                                                            |
| IB/0002             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                | 11/07/2024   | n/a          |               |                                                                                                                                            |